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Abstract
Pharmaceutical product information (PI) supplied by the regulatory authorities
serves as a source of information on safe and effective use of drugs. The objec-
tives of this study were to qualitatively and quantitatively compare PIs for
selected drugs marketed in both Denmark and the USA with respect to consis-
tency and discrepancy of listed adverse drug reaction (ADR) information. We
compared individual ADRs listed in PIs from Denmark and the USA with
respect to type and frequency. Consistency was defined as match of ADRs and
of ADR frequency or match could not be ruled out. Discrepancies were defined
as ADRs listed only in one country or listed with different frequencies. We ana-
lyzed PIs for 40 separate drugs from ten therapeutic groups and assigned the
4003 identified ADRs to System Organ Classes (Medical Dictionary for Regula-
tory Activities [MedDRA] terminology). Less than half of listed ADRs
(n = 1874; 47%) showed consistency. Discrepancies (n = 2129; 53%) were split
into ADRs listed only in the USA (n = 1558; 39%), ADRs listed only in Den-
mark (n = 325; 8%) and ADRs listed with different frequencies (n = 246; 6%).
The majority of listed ADRs were of the type “gastrointestinal disorders” and
“nervous system disorders”. Our results show great differences in PIs for drugs
approved in both Denmark and the USA illuminating concerns about the credi-
bility of the publicly available PIs. The results also represent an argument for
further harmonization across borders to improve consistency between author-
ity-supplied information.
Abbreviations
ADR, adverse drug reaction; ATC, Anatomical Therapeutic Chemical; DDD,
defined daily dose; DMA, Danish Medicines Agency; EMA, European Medicines
Agency; FDA, Food and Drug Administration; MAH, marketing authorization
holder; PI, product information; SOC, system organ class; SPC, Summary of Prod-
uct Characteristics.
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Introduction
Access to accurate and up-to-date information about safe
use of drugs is important for prescribers and dispensers.
The official product information (PI) serves as an author-
itative source of information (European Commission
2009; Food and Drug Administration 2013), which mar-
keting authorization holders (MAHs) are obliged to
update if new information is discovered. Inconsistencies
in this authority-supplied information would cause
healthcare professionals to base prescribing decisions on
different premises and unequal grounds. This is not only
problematic in the initiation of a drug treatment but also
influences any investigation of suspected adverse drug
reactions (ADRs).
Drug information from different resources that is
available to healthcare professionals has previously been
studied (Dunne et al. 1973; Silverman 1976; Alloza and
Lasagna 1983; Bawazir et al. 1991; Reggi et al. 2003;
Malinowski et al. 2008; Sawalha et al. 2008; Sasich et al.
2009; Sukkari et al. 2012). Few articles have compared
safety information listed in the PIs across countries and
regulatory systems. Garbe and Andersohn (2007)
assessed whether contraindications added to PIs from
the USA were also added to the German PIs. They
found that less than half of the contraindications added
to the PI in the USA had been fully incorporated and
listed in Germany. Nieminen et al. (2005) compared PIs
for biopharmaceuticals approved in the EU and the
USA. The authors reported that 14 of 32 PIs had the
same degree of detail, 15 were less detailed, and three
more detailed in the EU. Shimazawa and Ikeda (2013)
compared safety information in PIs from the USA, the
United Kingdom, and Japan by comparing the number
of words in sections concerning safety, and they con-
cluded that substantial differences in safety information
existed. Kesselheim et al. (2013) applied a similar
method. The PIs of 20 drugs from the USA, Canada,
the United Kingdom, and Australia were analyzed by
comparing the number of ADRs present in each coun-
try, and large differences were found. A recap (Prescr-
ire 2013) of cases in 2012 further provided incentive
to study the problem, by underlining multiple aspects
concerning drug safety issues.
The objectives of the present study was to qualitatively
and quantitatively compare PIs for selected drugs mar-
keted in both Denmark and the USA with respect to con-
sistency and discrepancy of listed ADR information. We
compared the individual listed ADRs of each drug with
respect to type and frequency across a broad range of
substances and MAHs.
Method
Selection of drugs
The basis for this analysis was all therapeutic groups at
the second Anatomical Therapeutic Chemical (ATC) clas-
sification system level (WHO Collaborating Centre for
Drug Statistics Methodology 2012). We used defined daily
dose (DDD) from the Danish population as a cut-off.
The threshold was set to minimum 50 sold DDD per
1000 inhabitants per day in year 2010 (Statens Serum
Institut 2012). We excluded combination drugs, drugs
not marketed by the original MAH in both Denmark and
the USA and drugs not available on the authorities’ web-
sites. The authorities’ websites were used to determine if
the drugs were currently marketed in Denmark (Læge-
middelstyrelsen 2012a) and the USA (Food and Drug
Administration 2012). We required the PIs to be issued
by the original MAH and the highest marketed strength
in Denmark and the USA to be the same.
Product information
In the EU, ADR information is presented in the document
called Summary of Product Characteristics (SPC) (Euro-
pean Commission 2009) and in the USA, the information
can be found in the drug’s label (Food and Drug Adminis-
tration 2013). In this article, we apply the terminology PI
for data from both countries. The PIs were retrieved from
the website of the respective regulatory agencies between
February and April 2012. Danish PIs were available from
either the Danish Medicines Agency (DMA) [now Danish
Health and Medicines Authority] (Læge-middelstyrelsen
2012b) or the European Medicines Agency (EMA) (Euro-
pean Medicines Agency 2012) depending on if the drug was
approved through the national or the centralised EU proce-
dure. FDA PIs were retrieved from Drugs@FDA (Food and
Drug Administration 2012).
Data collection and category assignment
For each included drug, we manually extracted all informa-
tion about ADRs and frequencies listed in the PIs. The same
type of ADR was only counted once (e.g., thirst and poly-
dipsia). The ADRs were assigned into the corresponding
Medical Dictionary for Regulatory Activities (MedDRA)
(Brown 2007) system organ class (SOC) or a separate cate-
gory for all data not possible to assign a SOC. Information
about seriousness of the ADRs listed in the PIs was scarce
and, therefore, this parameter was not included in this
study. All data extractions and analyses were made by the
fourth and fifth author and checked by the first author.
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Definition and classification of ADRs
Different terminology is applied in the countries and,
therefore, we use ADR to cover both undesirable effects
used in the EU and adverse reactions used in the USA.
The European Commission (European Commission 2009)
mandates ADR frequency information into five frequency
intervals plus an additional category ‘not known’
(Table 1), whereas the FDA (Food and Drug Administra-
tion 2006) advises to group ADRs within appropriately
specified frequency ranges. It is common practice that
drug labels approved by the FDA contain intervals quite
similar to the European intervals, but often with only
four intervals. We often observed the same definitions
used to describe fixed frequency intervals and we have
therefore based the analysis on the ranges these defini-
tions refer to (Table 1). Frequencies defined with a
numerical share were generalized into these intervals.
We defined consistency and discrepancy of ADR infor-
mation in eight categories (Table 2). Consistency was
specified as one of three conditions: First, ADRs listed as
occurring at the same frequency interval in both coun-
tries. Second, ADRs listed in both countries but without
information about the frequency. Third, ADRs possibly
listed with same frequency in both countries meaning that
due to the use of different frequency intervals, consistency
could not be dismissed. ADRs that were consistent under
the second and third conditions were merged in our
analysis. Discrepancy of ADR information was defined as
different frequencies listed in the countries or only listed
in one country. Difference in frequency was dichotomized
into ADRs with contiguous frequencies, consisting of
ADRs listed in two adjacent frequency intervals, and non-
contiguous frequencies, consisting of ADRs listed in two
nonadjacent frequency intervals. Information only listed
in one country was separated into a higher and a lower
interval (Table 1).
Data analysis of selected variables
We compared the approval agency, the approval date,
and the reported underlying clinical studies by compar-
ing the ADR distributions. The approval agency compar-
ison was between the EMA and the DMA, where we
used SPCs available from DMA and EMA. Drugs
approved before year 2000 was compared to drugs
approved year 2000 or later. In the analysis of the first
marketing date, the year 2000 was chosen as the Eur-
opean Commission guideline on the SPC structure
(European Commission 1999) was noticed to applicants
in December 1999. The newest guideline was released in
2009 (European Commission 2009) but few drugs only
have been approved under this guideline. We also com-
pared PIs where the ADR information was based on the
same underlying clinical study to where this could not
be identified. In the analysis of the underlying clinical
study, we only considered information stated in the
ADR section. The same study was determined from
either having the same number of participants in the
studies or the same study name. We did not distinguish
between studies leading to drug approval and postautho-
rization studies as in most cases it is not possible to
separate the two study types in the PIs.
Statistical analyses
We used a statistical approach to investigate if the ADRs
distributions differed by approval agency, approval date,
or clinical study used as base for the information. Initially
a chi-square test was performed on the two distributions
for each of the three previously stated variables. If this
showed a P-value less than 0.05, each of the eight catego-
ries that ADRs could be assigned to were tested against
all the other categories using Fisher’s exact test to identify
the category contributing to the difference. In addition to
investigating the eight categories, we also investigated if
the distributions of consistent ADRs and discrepant ADRs
were significantly different. The category that produced
the lowest P-value when tested against all other categories
was designated the contributing category and excluded
from further analysis. The procedure was iterated with a
new chi-square test, subsequent Fisher’s exact tests, and
exclusion of a category until no significant difference
between the distributions was found. Throughout the cal-
culations, Bonferroni correction was used to correct the
significance level for multiple testing.
Table 1. Definition of adverse drug reaction frequency intervals in Denmark and the USA.
Frequency European commission definition Definition often observed in PIs from the USA Frequency interval
≥1/10 Very common Frequent Higher frequency interval
≥1/100 to <1/10 Common Frequent Higher frequency interval
≥1/1000 to <1/100 Uncommon Infrequent Higher frequency interval
≥1/10,000 to <1/1000 Rare Rare Lower frequency interval
<1/10,000 Very rare Rare Lower frequency interval
Not estimated Not known Unknown Lower frequency interval
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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Results
Drug selection
Based on the selection criteria (Figure 1), only two diuretics
(C03) were eligible, but these were excluded as they only
had a DDD of 0.1 and 0.0 per 1000 inhabitants per day.
The group sex hormones and modulators of the genital sys-
tem (G03) was also excluded as this group mainly consists
of combination drugs and the DDDs of the remaining
drugs were low. The group antipsychotics (N05) and antide-
pressants (N06) were included due to the rapidly increasing
consumption of these drugs in Denmark. This resulted in
85 drugs which were reduced to 40 drugs spanning across
ten therapeutic groups by selecting the three drugs with
largest estimated DDD consumption in each second level
ATC group. Additional drugs that could be used to assess if
the approval agency, approval date, or clinical study simi-
larity influenced the results were also added.
Identified ADRs
The PIs for the 40 drugs listed totally 4003 ADRs
(Table 2), which were assigned into one of the eight
categories of consistency or discrepancy. ADRs listed with
corresponding frequencies made up 1398 (35%) of all
listed. Adding to this category, corresponding frequencies
cannot be dismissed resulted in 1874 (47%) consistency
between Denmark and the USA. The remaining 2129
(53%) showed discrepancy between PIs in the two coun-
tries. Among the discrepant ADRs, the largest part was
ADRs only listed in the USA that made up 1558 (39%),
whereas ADRs only listed in Denmark constituted 325
(8%). ADRs listed with frequency difference represented
246 (6%).
Consistency and discrepancy
We identified all ADRs listed in both countries (Table 3).
The largest proportion was found in the 673 ADRs with
unknown frequency in both countries. The largest pro-
portion of the 2129 discrepant ADRs was the 1558 (73%)
ADRs only listed in the USA. Of these, 326 were listed as
frequent, 440 as infrequent, 532 as rare, and 260 as
unknown. Among the 325 (15%) ADRs only listed in Den-
mark, two were listed as very common, 48 as common,
131 as uncommon, 76 as rare, 21 as very rare, and 47 as
not known. The ADRs identified as missing in one of the
countries span a broad range from less serious (e.g.,
flushing) to severe reactions (e.g., pulmonary embolism).
The remaining 246 (12%) of the 2129 discrepant ADRs
Figure 1. Flowchart of the procedure to select the analyzed sample. Drug selection was based on the therapeutic groups at the second ATC
level with DDDs over 50 per 1000 inhabitants per day. The procedure resulted in 40 drugs being selected and analyzed.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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were ADRs listed with frequency difference of which non-
contiguous frequency differences accounted for 48 (2%).
Consistencies and discrepancies were assigned to the
affected SOC (Figure 2). The largest numbers of both
consistent and discrepant ADRs were found in the SOCs
gastrointestinal disorders and nervous system disorders. We
found antidepressants (N06) to have more listed ADRs
than other therapeutic groups (Figure 3).
We further determined and compared the distribution
of ADRs based on approval agency, approval date, and
the reported clinical study (Table 4). Testing for differ-
ences between the distributions between EMA and DMA
demonstrated a significant difference (P < 0.001). The
categories contributing to the difference were ADRs only
listed in the USA as rare or unknown (P < 0.001) and
ADRs listed with contiguous frequency difference
(P = 0.002). There was no significant difference between
consistent ADRs and discrepant ADRs when comparing the
approval agencies (P = 0.041). We identified a difference
in the distributions between drugs approved before year
2000 and the ones in year 2000 or later (P = 0.003). The
category contributing to the difference was ADRs listed
with corresponding frequency (P = 0.002). No significant
difference was found between consistent ADRs and discrep-
ant ADRs (P = 0.166). Further, we found a significant dif-
ference in the distributions between ADR sections based
on the same clinical study and those that were not
(P < 0.001). Here, the categories contributing to the dif-
ference were ADRs only listed in the USA as frequent or
infrequent (P < 0.001) and ADRs only listed in the USA as
rare or unknown (P < 0.001). Additionally, the distribu-
tions of consistent ADRs and discrepant ADRs contributed
significantly (P < 0.001).
Discussion and Conclusions
The novelty in this work is that we have compared ADR
information for a large number of drugs across several
therapeutic groups. Our findings unveil large inconsisten-
cies between listed ADRs in PIs from Denmark and the
USA. To our knowledge, this is the first time individually
listed ADRs and their frequencies have been compared
between two countries. The results should be considered
conservative as we give the benefit of the doubt and,
therefore, do not classify all ADRs not displaying consis-
tent frequency as discrepancies, but also permit classifica-
tion, as corresponding frequencies cannot be dismissed.
However, when these two categories were merged to form
consistent ADRs, they still only account for 47%. It is not
comforting that we found such a large proportion of dis-
crepancies. The findings undoubtedly bring the question
about how similar data or even identical data in the cases
when referring to the same study can produce so different
information under such similar guidelines. This raises
concern about the credibility of PIs as a valuable informa-
tion source on safe drug use.
The largest proportion of discrepancies was explained
by ADRs only listed in one country and this could be
considered rather problematic as the information is com-
pletely missing in one of the countries. This still occurs
although the EMA and FDA PI guidelines are close to
identical in respect to presenting ADRs in the PIs. Fur-
ther, reports of ADRs should be conveyed between mar-
kets. Both guidelines state that all ADRs with a causal
relationship with the drug in question should be listed.
The FDA guideline clarifies this by explicitly stating that
reports on ADRs identified both domestically and in for-
eign countries should be included (Food and Drug
Administration 2006; European Commission 2009). It is
deeply concerning that we could identify severe ADRs
(e.g., pulmonary embolism) in only one country, which
should definitely be listed if causality was established. On
the other hand, long lists of rare and only possibly causal
ADRs could be causing information overload (Silverman
1976; Duke et al. 2011), through what Duke et al. (2011)
have labeled “overwarning.” This potentially makes it dif-
ficult to distinguish between different drugs’ safety pro-
files and choosing the most appropriate drug for the
patient. Additionally, long lists make the decision harder
about what information should be passed on to the
Table 3. Distribution of adverse drug reactions listed in production information issued in Denmark and the USA by frequency.
the USA\Denmark
Very common
(≥1/10)
Common (≥1/100
to <1/10)
Uncommon (≥1/1000
to <1/100)
Rare (≥1/10,000 to
<1/1000)
Very rare
(<1/10,000)
Not
known
Frequent (≥1/100) 559 103 23 3 24
Infrequent (<1/100 to ≥1/1000) 0 31 294 53 20 47
Rare (<1/1000) 0 2 11 99 32
Unknown 4 29 58 49 6 673*
*ADR listed as identified in post marketing in the USA and stated in Denmark (400), listed with terminology or intervals that do not allow deter-
mining if they are consistent neither can they be assigned into any other category (227), or unknown frequency in both countries (46).
Consistent frequencies are marked with bold.
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patient. The results from this study show similar propor-
tion of consistency as presented by Nieminen et al.
(2005). However, it should be pointed out that the
results of the two studies are not straightforward compa-
rable as no comparison was made of individual ADRs
and only biopharmaceuticals were compared in the study
by Nieminen and colleagues. In our study, biopharma-
ceuticals were not included. In addition, biologicals and
small molecule drugs are governed by different legislation
(Nieminen et al. 2005). Shimazawa and Ikeda (2013) and
Kesselheim et al. (2013) indicated that there were vari-
ances in the information provided in different countries.
In contrast, our study adds specific comparison of indi-
vidual ADRs listed for individual drugs between coun-
tries. As many clinical trial results are unpublished or
reported selectively (Gøtzsche and Jørgensen 2011), we
did not compare individual trials with the PIs. It would
be desirable to investigate which PI is more close to clin-
ical studies conducted by analyzing raw data (Barbui
et al. 2011). This might become reality as EMA has
flagged for its commitment to publish clinical trial infor-
mation (Cohen 2013) and thereby allow public investiga-
tion.
We argue that it cannot in any way be beneficial that
healthcare providers have access to different medical
information and we, therefore, stress the particular value
of further standardizing ADR presentation. We propose
a combination of the current PI layouts from Europe
and the USA, where in similar fashion as in Denmark,
a list of aggregated ADRs and their frequencies are pre-
sented in a general table. This section could be followed
by more detailed information and specific results from
clinical trials like in PIs from the USA, possibly also
including information on ADRs with weaker causal
links. This would provide the possibility to both get an
overview of a drug’s safety profile as well as allowing
detailed risk–benefit assessments for each patient.
Another possibility to adding the information in the PIs
is to separate the latter into a separate resource.
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Strengths and limitations of this study
In this study, we based the investigation on Denmark
and the USA. The situation in other EU and non-EU
countries might differ, and therefore the ADR labeling
status for the selected drugs may not be generalizable
to other countries and regulatory systems. Moreover,
we included only ADRs from the ADR sections unless
this referred to other sections. In spite of statements in
both European Commission and FDA guidelines (Euro-
pean Commission 2009; Food and Drug Administration
2013) to list all ADRs in the ADR section, it is possible
that ADRs have been listed in other sections of the PI
only and, therefore, were not included in the analysis.
Further, we cannot rule out that the same study was
used in both countries even though in our analysis
these have been assigned as not the same study. This is
because the MAH might use the same study but never
provide information about this in the PIs. The discrep-
ancies might also be due to differences in the legal
systems, where in the USA, an MAH might provide
unnecessarily many ADRs to prevent or lessen the
effect of a legal dispute. However, this has not been
investigated.
The approval agency did not significantly affect the
level of consistent ADRs. San Miguel et al. (2005) investi-
gated interaction information in PIs and found no differ-
ences among authorization procedures. Drugs approved
before 2000 and therefore marketed for a longer period of
time have not converged to a common profile. Despite
still having a high proportion of discrepancies, PIs of
drugs approved after 2000 showed improved consistency.
This could potentially be a result of the introduction of
the guideline in 2000, but this has not been investigated.
This finding undoubtedly brings the question about how
identical data under such similar guidelines are not even
close to being identical and raises concern about the cred-
ibility of ADR information in PIs from both Denmark
and the USA.
Although our findings were robust across the included
therapeutic categories, we cannot generalize to all other
categories of drugs.
In this study, we showed low consistency between PIs
for the same drugs marketed in both Denmark and the
USA. This occurred regardless of almost identical PI
guidelines in both countries. Currently, the ADR informa-
tion in PIs most likely is not accurate and up-to-date in
any of the two studied countries. This undermines the
PIs as the valuable information source on safe drug use
that they are intended to be. Regulatory agencies are
encouraged to make information about all clinically rele-
vant ADRs available to healthcare providers and patients
across countries.
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